#Asia-Pacific Topical Corticosteroids Market Forecast

[credenceresearchdotblog]

The Radiodermatitis Market is projected to grow from USD 471.68 million in 2023 to an estimated USD 674.26 million by 2032, registering a compound annual growth rate (CAGR) of 4.05% from 2024 to 2032.Radiodermatitis, also known as radiation-induced dermatitis, is a common side effect experienced by cancer patients undergoing radiotherapy. It manifests in varying degrees, ranging from mild redness and peeling to severe ulceration and necrosis. With the rising prevalence of cancer globally and increasing adoption of radiotherapy, the demand for effective treatments for radiodermatitis has grown significantly. The radiodermatitis market has witnessed substantial expansion, driven by advancements in treatment options, heightened awareness, and increased healthcare spending.

Browse the full report at https://www.credenceresearch.com/report/radiodermatitis-market

Market Drivers

Growing Cancer Cases According to the World Health Organization (WHO), cancer remains one of the leading causes of death worldwide. Radiotherapy is a cornerstone treatment for many cancer types, often causing radiodermatitis as a side effect. This has propelled demand for effective preventative and therapeutic measures, directly influencing the market.

Innovative Treatment Approaches Pharmaceutical and biotechnology companies are continuously innovating, developing advanced topical agents, gels, creams, and dressings specifically targeting radiodermatitis. Products like corticosteroid creams, hyaluronic acid-based dressings, and medical honey-based formulations are gaining traction for their efficacy and patient-friendly properties.

Rising Awareness and Support Programs Initiatives by healthcare organizations and patient advocacy groups to raise awareness about the importance of managing radiodermatitis have played a crucial role in market growth. Educational campaigns ensure that patients and healthcare providers are better informed about available treatments.

Expanding Healthcare Infrastructure Emerging economies are investing heavily in their healthcare systems, enabling better access to radiotherapy and related care. This creates opportunities for radiodermatitis treatment providers to tap into these growing markets.

Challenges in the Market

High Costs of Advanced Treatments Innovative radiodermatitis treatments, while effective, are often expensive. This can limit access for patients in low- and middle-income countries.

Limited Standardized Guidelines The absence of universally accepted guidelines for radiodermatitis management leads to variations in treatment practices, which may hinder the adoption of specific products.

Side Effects of Treatments Some treatments for radiodermatitis come with their own side effects, potentially discouraging their use.

Future Outlook

The radiodermatitis market is poised for significant growth in the coming years, driven by technological advancements and an increased focus on improving patient quality of life. Innovations like nanotechnology-based treatments and the integration of artificial intelligence for personalized care are expected to revolutionize the market. Moreover, government and private-sector initiatives to improve healthcare access in developing countries will further boost market growth.

Key players

3M

Mölnlycke Health Care AB

KCI Licensing Inc.

Smith & Nephew

Helsinn Healthcare SA

Stratpharma AG

Helsinn Healthcare SA

Segments

Based on Product

Hydrogel & Hydrocolloid Dressings

No-Sting Barrier Films

Silver Leaf Dressings

Silicone-Coated Dressings

Corticosteroids and Hydrophilic Creams

Others

Based on Route of Administration

Topical

Oral

Based on Distribution Channel

Hospitals

Cancer Specialist Clinics

Research Institutes

Others

Based on Region

North America

Europe

Asia-Pacific

Rest of the World

Browse the full report at https://www.credenceresearch.com/report/radiodermatitis-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

[harshnews]

Psoriasis Treatment Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Global Psoriasis Treatment Market - Industry Trends and Forecast to 2029

Global Psoriasis Treatment Market, By Drug Class (Corticosteroids, TNF Inhibitors, Interleukins, Others), Type (Plaque Psoriasis, Psoriatic Arthritis, Others), Route of Administration (Oral, Parenteral, Topical), Application (Topical Therapeutic Drugs, Systemic Therapeutic Drugs, Combinations), End User (Hospital Pharmacy, Clinics, Retail Pharmacies, Online Sales), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **By Drug Class**: The psoriasis treatment market can be segmented based on drug class, which includes biologics, systemic therapy, topical therapy, and others. Biologics are becoming increasingly popular due to their targeted approach in treating psoriasis at a molecular level. Systemic therapy involves oral or injectable medications that affect the entire immune system to manage psoriasis symptoms. Topical therapies include creams, ointments, and lotions applied directly to the skin to alleviate mild to moderate symptoms.

- **By Route of Administration**: Another important segmentation in the psoriasis treatment market is based on the route of administration. This includes oral, injectable, and topical routes. Oral medications are often prescribed for systemic treatment, while injectable biologics are administered via subcutaneous or intravenous routes. Topical treatments are primarily used for localized psoriasis management.

- **By Distribution Channel**: The distribution channel segment categorizes the market based on where patients can access psoriasis treatments. This includes hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. Hospital pharmacies are common for inpatient treatments, while retail pharmacies cater to outpatient prescriptions. Online pharmacies are gaining popularity due to convenience, and specialty clinics focus on dermatological care for psoriasis patients.

**Market Players**

- **AbbVie Inc.**: AbbVie is a leading player in the psoriasis treatment market, offering biologics like Humira (adalimumab) for psoriasis management.

- **Johnson & Johnson Services, Inc.**: Johnson & Johnson is known for its systemic therapy options for psoriasis, such as Stelara (ustekinumab) and Tremfya (guselkumab).

- **Novartis AG**: Novartis is a key player with a strong portfolio of psoriasis treatments, including Cosentyx (secukinumab) and Methotrexate.

- **Amgen Inc.**: Amgen has a range of biThe psoriasis treatment market is a dynamic and evolving sector with several key players driving innovation and advancements in treatment options for patients. AbbVie Inc. is a prominent player in the market, offering biologics like Humira (adalimumab) that have demonstrated efficacy in managing psoriasis symptoms. Biologics have gained significant traction in the market due to their targeted approach at the molecular level, offering a more personalized and effective treatment option for patients. Johnson & Johnson Services, Inc. is another major player known for its systemic therapy options such as Stelara (ustekinumab) and Tremfya (guselkumab), which have shown promise in managing moderate to severe psoriasis.

Novartis AG, with its strong portfolio of psoriasis treatments including Cosentyx (secukinumab) and Methotrexate, has been instrumental in improving outcomes for patients with psoriasis. These treatments target specific pathways involved in the development of psoriasis, providing patients with more targeted and effective treatment options. Amgen Inc., with its range of biologics like Enbrel (etanercept), has also made significant contributions to the market by providing new insights and advancements in psoriasis treatment.

The market for psoriasis treatments is witnessing a shift towards more personalized and targeted therapies, driven by advancements in biologics and systemic therapies. Biologics, in particular, have revolutionized the treatment landscape for psoriasis by targeting specific molecules involved in the inflammatory response associated with the condition. These targeted therapies have shown significant efficacy in managing psoriasis symptoms and improving quality of life for patients.

The distribution channels for psoriasis treatments play a crucial role in ensuring access to these therapies for patients. Hospital pharmacies are essential for inpatient treatments, while retail pharmacies cater to outpatient prescriptions, providing convenient access to medications for patients. Online pharmacies have also emerged as a popular choice for patients seeking convenience and accessibility in obtaining their psoriasis treatments. Specialty clinics focusing on dermatological**Global Psoriasis Treatment Market**

- **Segments** - **By Drug Class**: The psoriasis treatment market encompasses a variety of drug classes, including corticosteroids, TNF inhibitors, interleukins, and others. Corticosteroids are commonly used for their anti-inflammatory properties, while TNF inhibitors and interleukins target specific pathways in the immune system to manage psoriasis symptoms. Other drug classes offer alternative mechanisms of action for psoriasis treatment. - **By Type**: The types of psoriasis targeted in the market include plaque psoriasis, psoriatic arthritis, and other less common forms of the condition. Different types of psoriasis may require specific treatment approaches tailored to the patient's symptoms and disease progression. - **By Route of Administration**: Psoriasis treatments can be administered through various routes, such as oral, parenteral, and topical. Oral medications are often used for systemic treatment, while parenteral routes involve injections for targeted therapy. Topical treatments are applied directly to the skin for localized symptom management. - **By Application**: The applications of psoriasis treatment include topical therapeutic drugs, systemic therapeutic drugs, and combination therapies. These different applications offer a range of options for patients and healthcare providers to address the varying severity of psoriasis symptoms. - **By End User**: The end users in the psoriasis treatment market span hospital pharmacies, clinics, retail pharmacies, and online sales. Each end user plays a crucial role in ensuring access to psoriasis

The Psoriasis Treatment Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.

Major Points Covered in TOC:

Psoriasis Treatment Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, Psoriasis Treatment Market portions by application, study goals, and years considered.

Psoriasis Treatment Market Landscape: Here, the opposition in the Worldwide Psoriasis Treatment Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.

Psoriasis Treatment Profiles of Manufacturers: Here, driving players of the worldwide Psoriasis Treatment Market are considered dependent on deals region, key items, net edge, income, cost, and creation.

Psoriasis Treatment Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide Psoriasis Treatment Market is profoundly examined based on areas and nations like North America, Europe, China, India, Japan, and the MEA.

Psoriasis Treatment Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Psoriasis Treatment Market.

Psoriasis Treatment Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.

Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

What to Expect from the Report, a 7-Pointer Guide

The Psoriasis Treatment Market report dives into the holistic Strategy and Innovation for this market ecosystem

The Psoriasis Treatment Market report keenly isolates and upholds notable prominent market drivers and barriers

The Psoriasis Treatment Market report sets clarity in identifying technological standardization as well as the regulatory

framework, besides significantly assessing various implementation models besides evaluation of numerous use cases

The Psoriasis Treatment Market report is also a rich repository of crucial information across the industry, highlighting details on novel investments as well as stakeholders and relevant contributors and market participants.

A through market analytical survey and forecast references through the forecast tenure, encapsulating details on historical developments, concurrent events as well as future growth probability

Browse Trending Reports:

Calcium Glycinate Market Retinal Biologics Market Facial Fat Transfer Market Angio Suites Diagnostic Imaging Market Adoption Of Benelux Power Tools Market De Quervains Tenosynovitis Treatment Market Biodetectors And Accessories Market Colposcope Market Sports Medicine Market Automotive Adhesives Market Infrared Imaging Market Vapour Deposition Market Professional Diagnostics Market Ct Scanner Market Programmable Application Specific Integrated Circuit Asic Market Hospital Operating Room Or Products And Solutions Market Castor Oil Market Zika Virus Infection Drug Market Toluene Diisocynate Market Antibiotic Resistance Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[colinwilson11]

Digitalization Will Propel The Bullous Pemphigoid Market Growth Owing To Increased Diagnosis Accuracy

The Bullous Pemphigoid Market involves treating a rare autoimmune disease wherein the immune system attacks the skin and mucous membranes resulting in large fluid-filled blisters and vesicles on the skin and mucosal membrane. Bullous Pemphigoid primarily affects the elderly population above the age of 60 and leads to extensive itching and pain. The main treatment modalities involve immunomodulatory medications such as corticosteroids, anti-inflammatory drugs, and immunosuppressive medications to ease symptoms.

The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.

Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. These companies offer a range of treatment options from oral and topical corticosteroids to immunosuppressive therapies. The increasing geriatric population prone to developing bullous pemphigoid coupled with rising awareness regarding the condition is expected to drive the growth of the market. Additionally, advancements in diagnosis facilitated by digital imaging technologies assist in prompt diagnosis and treatment of the condition, thereby improving treatment outcomes.

Key Takeaways

Key players analysis: Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. GlaxoSmithKline leads the market with drugs including Rituximab and Benlysta.

Growing demand: The growing geriatric population accounted for a major share of the bullous pemphigoid patient pool. According to the WHO, the number of people aged 60 years and older is expected to double by 2050. This significantly drives the demand for bullous pemphigoid treatment.

Technological advancement: Advancements in digital imaging and teledermatology allow accurate diagnosis of bullous pemphigoid through visualization of skin lesions via smartphones and teleconsultation. This enables early intervention and superior management of the condition.

Market Trends

Combination therapies: There is a growing trend of using drug combinations as opposed to monotherapies to effectively manage bullous pemphigoid. Popular combinations involve corticosteroids with immunosuppressants.

Targeted biologic agents: Novel targeted biologic agents aimed at specific antibodies and immune pathways involved in bullous pemphigoid show promise. Drugs like Rituximab, Inebilizumab, and Eculizumab are being evaluated for efficacy and safety.

Market Opportunities

Emerging economies: Countries in Asia Pacific and Latin America present lucrative opportunities for bullous pemphigoid treatment providers owing to growing medical needs of their aging population and economic expansion.

Online consultations: Telehealth and e-pharmacy platforms allow people to remotely access bullous pemphigoid specialists and medication, thereby overcoming distance barriers. This increases access to care.

Impact Of COVID-19 On Bullous Pemphigoid Market Growth

The COVID-19 pandemic has significantly impacted the growth of the bullous pemphigoid market. During the initial phases of the pandemic between 2020-21, the market witnessed a decline in growth rate owing to lockdowns imposed across various countries. This led to postponement of non-essential dermatological procedures and treatments. Patients also avoided visiting healthcare facilities fearing exposure to the virus. As a result, diagnosis and treatment rates for bullous pemphigoid reduced considerably during this period.

However, with lifting of lockdowns and rollout of vaccination drives globally, the market has started recovering post 2021. Increased awareness about the autoimmune disorder and availability of effective treatment options are supporting the growth trajectory. Various initiatives undertaken by key market players to ensure uninterrupted supply of drugs and therapies have also boosted market revenues. For instance, companies streamlined their production and distribution channels to meet the rising demand. Teleconsultations further aided continued care for patients during lockdowns.

Going forward, the bullous pemphigoid market is expected to witness robust expansion supported by ageing population prone to developing the condition. Moreover, rapid advancements in biologics and targeted therapies will expand treatment options. Players are investing heavily in R&D to develop novel pipeline drugs. Favorable regulatory environment and reimbursement policies will augment market access. Widespread vaccination drives and resumption of normal healthcare activities will further accelerate market growth in the coming years.

Europe holds the largest share of bullous pemphigoid market in terms of value owing to sizeable patient pool and high treatment uptake. North America follows Europe in terms of revenue generation led by rising disease prevalence and advanced healthcare infrastructure. Asia Pacific is recognized as the fastest growing regional market and will continue exhibiting strong growth momentum through 2031. This can be attributed to improving access to diagnosis and treatment options due to expanding healthcare expenditure in countries like China and India.

Geographical Regions With Highest Bullous Pemphigoid Market Value

North America accounts for the largest share of the Bullous Pemphigoid Market value-wise. The region is estimated to hold over 35% revenue share of the overall market in 2024 led by strong presence of leading pharmaceutical companies in US and Canada. Increased focus on research into novel treatment options along with supportive reimbursement policies are driving the growth of the North America bullous pemphigoid market.

Europe holds the second largest value share globally on account of rising burden of the autoimmune disorder due to aging population. Countries like Germany, UK, France, Italy are major revenue generators for Europe bullous pemphigoid market. High healthcare expenditure and availability of affordable treatments make Europe an attractive regional market.

Geographical Region Witnessing Fastest Growth In Bullous Pemphigoid Market

Asia Pacific region has emerged as the fastest growing geographical market for bullous pemphigoid globally. The Asia Pacific bullous pemphigoid market is projected to expand at a CAGR of over 12% during 2024-2031. Factors such as growing geriatric demographic, increasing medical awareness regarding bullous pemphigoid diagnosis and management, rising healthcare spending, and improving access to advanced drugs are fueling the market growth. Countries like India, China, Japan, and South Korea are expected to drive substantial revenues for bullous pemphigoid treatment manufacturers within Asia Pacific market.

Get more insights on this topic:  https://www.ukwebwire.com/bullous-pemphigoid-market-growth-to-be-fueled-by-advancements-in-targeted-therapies/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Bullous Pemphigoid Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors

FAQ’s

Q.1 What are the main factors influencing the Bullous Pemphigoid Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[wellnessweb]

Global Dyspnea Treatment Market Size and Trends

The Dyspnea Treatment Market size was estimated at USD 6.30 billion in 2023 and is expected to reach USD 10.82 billion by 2031 with a growing CAGR of 7% during the forecast period of 2024-2031.The dyspnea treatment market is experiencing significant growth driven by the rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and COVID-19-related complications. Advancements in diagnostic technologies and therapeutic approaches, including pharmacological interventions, oxygen therapy, and non-invasive ventilation, are enhancing patient outcomes and expanding market opportunities. Emerging treatments like novel bronchodilators, biologics, and gene therapies are attracting substantial investments from pharmaceutical companies and research institutions.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3938

Market Scope & Overview

The research looks into the major variables affecting the expansion of the global market. The report used a bottom-up approach to gather and forecast data for a wide range of industrial verticals and end-user industries, as well as their reach across several categories, in order to determine the overall size of the Dyspnea Treatment Market throughout the forecast period. Market actors may use market data to create plans to improve their competitive position.

The Dyspnea Treatment Market research report covers all of these topics in great detail, including the Porter's Five Forces analysis, significant segments, drivers, opportunities, and the competitive environment. For business experts, stakeholders, investors, VPs, and newcomers who want to learn more about the company and formulate a competitive strategy, this study is an excellent resource.

Market Segmentation Analysis

By Type

Therapies

Supplemental Oxygen Therapy

Relaxation Therapy

Drugs

Antianxiety Drugs

Antibiotics

Anticholinergic Agents

Corticosteroids

Others

By Route of Administration

Oral

Inhalation

Others

By End User

Hospitals

Home Care

Specialty Centres

COVID-19 Impact Analysis

Due to the COVID-19 lockout, it was necessary to create original strategies for dealing with future occurrences while sustaining steady growth. The market research report also provides advice for overcoming pandemic-like situations and lessening their harmful effects. The Dyspnea Treatment Market was significantly impacted by the COVID-19 epidemic. Due to delays in new developments, the industry has also been suspended internationally.

Regional Outlook

With a focus on North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa, the Dyspnea Treatment Market research report digs into market aspects including estimations for total price from top manufacturers and trends toward advancement in various regions of the world.

Competitive Analysis

The research report offers a complete analysis of the worldwide Dyspnea Treatment Market and suggests important adjustments that market players should take into account when developing their business plans. To gain market dominance, these companies have used partnerships, product development, joint ventures, mergers and acquisitions, diversification, and joint ventures.

Key Reasons to Purchase Dyspnea Treatment Market Report

To identify important geographic regions and leading nations that have a substantial impact on market revenue, the researchers conduct geographic study.

Prospect information may be used by market participants to evaluate potential and formulate their next moves.

Report Conclusion

Manufacturers, distributors, dealers, and policymakers may use the data from the market research report to assess which industry sectors should be prioritized in the upcoming years in order to plan investments and take advantage of the Dyspnea Treatment Market expansion.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Glaucoma Therapeutics Market Trends

DNA Synthesis Market Trends

Genomics Services Market Trends

Immunomodulators Market Trends

Lymphoma Treatment Market Trends

[bizworldinsights]

Osteoarthritis

In 2019, the global osteoarthritis market is estimated to be valued at over US$ 2,205 million, projecting a robust CAGR of 9.1% from 2019 to 2028. This marks a significant 2.2X increase in revenue opportunity by 2028 compared to 2018. The industry landscape is characterized by consolidation, with major players heavily invested in R&D endeavors, particularly focused on the development of cell-mediated drugs. A transformative shift is anticipated as a considerable number of clinical trials progress into phases III and IV.

To read more about the topic please visit site : https://bekryl.com/industry-trends/osteoarthritis-market-share-analysis

Key Trends and Drivers Fueling Osteoarthritis Market Demand:

The prevalence of osteoarthritis cases has surged over the last decade, reaching over 316 million cases globally in 2019. Projections indicate an increase to 381 million cases by 2028. This rise in cases is driving the demand for effective treatment options, predominantly in medicated forms.

The competitive landscape is expected to intensify in the latter part of the forecast period (post-2024). The majority of products are currently under trial in phase II of FDA testing. Upon approval, this will lead to heightened competition, significantly impacting the market share of key players. Approximately half of the products are undergoing phase III and IV trials, with a concentration of clinical trials in North America, followed by Western Europe. Japan and South Korea are pivotal regions in Asia Pacific, witnessing clinical trials evaluating product efficacy. Pfizer stands out with the highest number of clinical trials and dominated the osteoarthritis market share in 2018.

Merger and acquisition activities are expected to be a prominent trend in the market. The heightened competition will drive companies to acquire the technological and market competencies of established players. Notably, in 2018, Mundipharma strategically collaborated with Kolon Life Sciences to market Invossa®-K in Saudi Arabia and the United Arab Emirates, with subsequent extension to Japan. Invossa®-K, the world's first cell-mediated gene therapy for osteoarthritis, received approval in 2017 from the Korean Ministry of Food and Drug Safety (MFDS).

Global Osteoarthritis Market Size, Segment Analysis:

Drug Class: Corticosteroids, NSIADs, and Viscosupplementation Agents contribute to industry revenue. Viscosupplementation is expected to witness the highest growth during the forecast period.

Route of Administration: The market revenue for osteoarthritis drugs is analyzed based on oral drugs, parenteral drugs, and topical drugs. Oral-based OA drugs held the highest share in 2018 and are anticipated to maintain this trend throughout the forecast period.

Distribution Channel: Revenue analysis spans hospitals, drugstores, pharmacies, and online channels. While online channels held the lowest share, they are projected to experience double-digit growth. Major players are actively investing in online channels to enhance purchasing convenience for customers and foster long-term retention.

Global Osteoarthritis Market Size, Regional Outlook:

North America: Witnessed the highest osteoarthritis drug sales in 2018, contributing to 57% of total market revenue. With over 61 million people in the U.S. suffering from OA, the region provides a sizable addressable market. The U.S. sees robust sales of biologic analgesics such as Regeneron’s fasinumab, TissueGene’s Invossa, and Pfizer’s tanezumab.

Asia Pacific: Expected to register the fastest growth during the forecast period. Japan and China hold the highest OA market share in 2019, with Japan's market valued at US$ 169 million in 2018. China and India are projected to achieve double-digit growth due to increased healthcare FDI and improved healthcare infrastructure. Favorable reimbursement policies, such as India's Ayushman Bharat, are poised to make healthcare more accessible to lower-income individuals, boosting spending on osteoarthritis treatment in the region.

Global Osteoarthritis Market Size, Competitive Landscape:

Key industry players include Pfizer, Cara Therapeutics, Mitsubishi Tanabe Pharma, Ampio Pharmaceuticals, Cellular Biomedicine Group, Teva Pharmaceutical, Eli Lilly, Techfields Pharma, Healthcare Life Sciences, Seikagaku Corp, Kolon Life Sciences, Flexion Therapeutics, Ono Pharmaceutical, Regeneron Pharmaceuticals, Mundipharma, Samumed, Centrexion Therapeutics, TissueGene, among others.

Research Scope:

By Drug Class:

Corticosteroids

NSIADs

Viscosupplementation Agents

By Route of Administration:

Oral

Parenteral

Topical

By Distribution Channel:

Drugstores

Pharmacies

Hospital Stores

Online Pharmacies

The global osteoarthritis market is poised for substantial growth, driven by escalating cases, evolving clinical trials, and significant advancements in treatment options. As the industry progresses into higher phases of FDA testing, competition will heighten, creating a dynamic landscape. Emerging markets, particularly in Asia Pacific, are expected to play a pivotal role in shaping the future of osteoarthritis treatment, presenting lucrative opportunities for industry players.

[creative-news-alert]

Pruritus Therapeutics Market Estimated to Witness High Growth Owing to Increasing Prevalence of Pruritis

Pruritus therapeutics refers to drugs that provide relief from itching. Pruritis, commonly known as itch, is a distressing sensation that prompts the desire to scratch. Prescription products used in pruritus therapeutics include topical corticosteroids, topical calcineurin inhibitors, oral H1-antihistamines, histamine antagonists, and others. These drugs help reduce itching associated with various dermatological conditions like eczema, psoriasis, dermatitis, and insect bites. The global pruritus therapeutics market is estimated to be valued at US$ 70.64 Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The pruritus therapeutics market is expected to witness significant growth during the forecast period owing to increasing prevalence of pruritis. According to the International Forum for the Study of Itch, over 20% of adults in the U.S. suffer from chronic pruritus, which causes an itch that lasts longer than 6 weeks. Moreover, increasing prevalence of pruritis causing conditions like atopic dermatitis, psoriasis and chronic pruritic diseases is also expected to propel market growth over the forecast period. One of the key drivers for the pruritus therapeutics market is increasing prevalence of pruritis. According to a study published in the U.S. National Library of Medicine National Institutes of Health, the prevalence of pruritus ranges from 2% to 5% worldwide. SWOT Analysis Strength: Pruritus Therapeutics focuses on developing treatments for chronic pruritus, an area lacking effective therapeutic options. The large unmet need can drive significant demand for innovative solutions. Over 70 million patients in major markets suffer from pruritus. Developing safe and effective therapies can help improve quality of life for many patients and capture a sizable market share. Weakness: Developing treatments targeting the complex pathophysiology of chronic pruritus is scientifically challenging. Underlying causes often remain unknown, limiting the ability to address root drivers. High failure rates in clinical trials are common in this therapeutic area. Financial resources required to advance multiple candidates through research and development are substantial. Opportunity: Growing geriatric populations prone to conditions like atopic dermatitis and kidney disease present an expanding pool of potential patients. Increased understanding of neural pathways involved in itch sensation point to novel targets. Partnerships with dermatologists and allergists can help accelerate clinical adoption. Combination products targeting multiple pathways may improve outcomes over monotherapies. Threats: Generic competition may erode sales of existing branded therapies as patents expire. Failure to demonstrate clear efficacy advantages over current options in registration trials poses a risk. Potential safety issues uncovered in later stages of development could hamper uptake or lead to withdrawals. Rising development costs and investment required to stay competitive also present challenges. Key Takeaways The global Pruritus Therapeutics market size is expected to witness high growth.

North America currently dominates due to high disease prevalence, strong reimbursement structures, and concentration of major players. However, Asia Pacific is poised to expand rapidly over the forecast period as improving access to care and economic development drive increased diagnosis and treatment rates across major countries like China and India. Key players operating in the Pruritus Therapeutics market are Levantina, Polycor, Indian Natural Stones, Topalidis, Dermitzakis, Antolini, Arizona Tile, Vetter Stone, Tekmarble & Granite, Temerty Stone, Dal Tile, M S International, Pokarna Limited, Cosentino. These companies have a strong existing portfolio of approved drugs and candidates in development. Strategic partnerships and acquisitions allow them to diversify their product pipelines and commercial footprints into new therapeutic areas and geographical territories respectively.

Get more insights on this topic: https://www.newswirestats.com/pruritus-therapeutics-market-size-and-outlook/ Explore more information, Please visit:https://filmik.in/cracking-the-code-of-epigenetics-the-harmony-of-gene-expression-outside-of-dna/

[jayanthitbrc]

Unlocking the Future of Alopecia Areata Treatment: Global Market Insights 2023-2032 || Pfizer Inc., Merck & Co. Inc., AbbVie Inc

The Business Research Company’s Alopecia Areata Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Alopecia Areata Global Market Report 2023 evaluates alopecia areata market size, growth rate, drivers, trends, and major companies. The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. Request A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample_request?id=12596&type=smp The global alopecia areata market is expected to grow from $3.08 billion in 2022 to $3.31 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The alopecia areata market is expected to reach $4.35 billion in 2027 at a CAGR of 7.1%. The growing prevalence of hair loss is expected to propel the growth of the alopecia areata market going forward. Hair loss is caused by disrupting the body's normal hair growth cycle. Alopecia areata treatment employs corticosteroids, potent anti-inflammatory medications that can inhibit the immune system, to treat a condition where the immune system destroys hair follicles and results in hair loss. For instance, in March 2022, according to an article by the Hair Society, a US-based full-service professional organization, hair loss affected about 21 million women and 35 million men globally. The majority of people in the world will lose their hair starting at age 35, with a 40% loss rate for males and increasing to a 70% loss rate for men at age 80. Women with hair loss will account for 80% or more by age 60. Therefore, the growing prevalence of hair loss is driving the growth of the alopecia areata market. Get More Information On The Alopecia Areata Market Report:

https://www.thebusinessresearchcompany.com/report/alopecia-areata-global-market-report The alopecia areata market segments in the report are: 1) By Type: Patchy Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Diffuse Alopecia Areata, Ophiasis Alopecia, Other Types 2) By Treatment: Medical Treatments, Natural Treatment, Other Treatments 3) By Diagnosis: Trichoscopy, Skin Biopsy, Other Diagnoses 4) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users The table of contents in TBRC’s alopecia areata market report includes:

1. Executive Summary

2. Alopecia Areata Market Characteristics

3. Alopecia Areata Market Trends And Strategies

4. Alopecia Areata Market - Macro Economic Scenario . . . 32. Global Alopecia Areata Market Competitive Benchmarking

33. Global Alopecia Areata Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alopecia Areata Market

35. Alopecia Areata Market Future Outlook and Potential Analysis

36. Appendix Learn About Us:  The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:  The Business Research Company  Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[rohans18]

Asia-Pacific Dermatology Drugs Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2028

Global Asia-Pacific Dermatology Drugs Market, By Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), Prescription mode  (Prescription Based Drugs, Over Counter Drugs), Drug Classification (Corticosteroids, Astringents, Anti-Inflammatory & Antipruritic Drugs, Anti-Infective/Antibacterial Drugs, Antifungal Drugs), Route Of Administration (Topical, Oral, Parenteral Administration), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Speciality Clinics, Cosmetic Centres) – Industry Trends and Forecast to 2029

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Asia-Pacific Dermatology Drugs marketing report. The report has a lot to offer to both established and new players in the Asia-Pacific Dermatology Drugs industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Asia-Pacific Dermatology Drugs market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

Abbott (U.S.)

Wondfo (China)

OraSure Technologies, Inc. (U.S.)

Quest Diagnostics Incorporated. (U.S.)

NEOGEN CORPORATION (U.S.)

Oranoxis Inc. (U.S.)

Premier Biotech, Inc. (U.S.)

(U.S.)

AccuBioTech Co., Ltd (China)

MEDACX Ltd. (U.K.)

Oasis Diagnostics Corporation (U.S.)

Porex (U.S.)

Salimetrics, LLC (U.S.)

Browse More Info @ https://www.databridgemarketresearch.com/reports/asia-pacific-dermatology-drugs-market  

With the help of credible Asia-Pacific Dermatology Drugs market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Asia-Pacific Dermatology Drugs market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Asia-Pacific Dermatology Drugs Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[adityarana1687-blog]

Alopecia Market Is Expected To Grow Swiftly By 2030

The global alopecia market size is expected to reach USD 16.02 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.0% from 2023 to 2030. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.

The prevalence of alopecia areata (AA) and alopecia totalis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.

The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly’s Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer’s Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.

Another key factor driving the industry’s growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.

The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.

Request a free sample copy or view report summary: Alopecia Market Report

Alopecia Market Report Highlights

In 2022, the AA segment dominated the alopecia industry with a revenue share of 35.13% and is anticipated to maintain its pole position throughout the forecast period

The alopecia universalis segment is expected to witness the fastest growth from 2023 to 2030, owing to the impending approval of pipeline products, such as Pfizer’s Ritlecitinib which is in the pre-registration phase, and Bioniz Therapeutics’s BNZ-1 which is in phase 2 clinical trials

North America dominated the market in 2022, mainly due to the high consumer awareness, technological advancements, high target disease population, and high healthcare spending

Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be majorly attributed to the rising target disease population and rising treatment rate for the disease

A few of the key market players include Janssen Global Services Inc.; Cipla Limited; Merck & Co., Inc.; GlaxoSmithKline plc; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; Aurobindo Pharma; Viatris Inc.

Alopecia Market Segmentation

Grand View Research has segmented the global alopecia market based on disease type, treatment, gender, sales channel, end-use, and region:

Alopecia Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

Alopecia Areata

Male

Female

Cicatricial Alopecia

Male

Female

Traction Alopecia

Male

Female

Alopecia Totalis

Male

Female

Alopecia Universalis

Male

Female

Androgenetic Alopecia

Male

Female

Others

Male

Female

Alopecia Treatment Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceuticals

Topical

OTC

Minoxidil

Others

Prescription

Betamethasone Dipropionate

Fluocinolone Acetonide

Finasteride

Minoxidil

Oral

OTC

Prescription

Minoxidil

Finasteride

Corticosteroids

Others (JAK inhibitors and others)

PRP

Devices

Laser Cap

Laser Comb

Laser Helmet

Alopecia Gender Outlook (Revenue, USD Million, 2018 - 2030)

Male

Female

Alopecia Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

Prescriptions

OTC

Alopecia End-use Outlook (Revenue, USD Million, 2018 - 2030)

Homecare Settings

Dermatology Clinics

Alopecia Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S

Canada

Europe

UK

Germany

Spain

France

Italy

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Alopecia Market

Johnson & Johnson Services, Inc

Merck & Co., Inc.

Cipla Limited

Sun Pharmaceuticals Industries Ltd

Dr. Reddy's Laboratories Ltd

GlaxoSmithKline plc.; Aurobindo Pharma

Viatris Inc.

Pfizer, Inc.

Lilly

Lexington Intl., LLC (Devices)

Freedom Laser Therapy (iRestore ID-520 helmet)

Curallux, LLC.

Apira Science Inc. (iGROW Laser)

Revian Inc.

Theradome

Lutronic

[kdmarket]

Chronic Gingivostomatitis Treatment Market: Growth Potential and Development Forecast-2032

The global chronic gingivostomatitis treatment market is expanding rapidly, propelled by an increase in the incidence of chronic gingivostomatitis and a greater awareness of the importance of oral health. Chronic gingivostomatitis is a severe inflammatory condition of the gums and oral cavity that causes pain, inflammation, and ulceration. This condition has a substantial impact on an individual's quality of life, necessitating the development of effective treatments. In the approaching years, the chronic gingivostomatitis treatment market is anticipated to expand significantly.

The increasing prevalence of chronic gingivostomatitis worldwide is one of the main growth drivers for the chronic gingivostomatitis treatment market. Contributing to the development of chronic gingivostomatitis are factors such as inadequate oral hygiene, smoking, stress, and a compromised immune system. It is anticipated that the incidence of chronic gingivostomatitis will increase as the global population grows. This, in turn, is propelling the growth of the market by increasing the demand for effective treatment options.

In addition, growing awareness of oral health and the significance of early intervention in the management of chronic gingivostomatitis is driving market expansion. Dental organisations, healthcare professionals, and oral health campaigns are actively promoting oral hygiene and the significance of regular dental examinations. This increased awareness is encouraging individuals to seek treatment for chronic gingivostomatitis in a timely manner, thereby driving market growth.

However, there are obstacles on the chronic gingivostomatitis treatment market. One of the greatest obstacles confronted by patients and healthcare providers is the limited availability of innovative treatment options. Currently, the treatment focuses primarily on symptom management, pain alleviation, and inflammation reduction. Chronic gingivostomatitis requires innovative therapeutic approaches that target its underlying causes. There are ongoing research and development efforts to create novel treatments with improved patient outcomes.

The market for chronic gingivostomatitis treatments can be segmented by treatment type, end-user, and region. The market can be segmented by treatment type into topical medications, oral medications, and surgical interventions. For the management of symptoms, topical medications such as corticosteroids and antiseptics are commonly prescribed. For systemic management, oral medications, such as antibiotics and immunosuppressants, are utilised.

In severe cases, surgical interventions such as gingivectomy and laser therapy may be recommended.

Hospitals, dental clinics, and ambulatory surgical centres are the end-users for chronic gingivostomatitis treatment. Due to the availability of specialised oral health departments and an extensive spectrum of treatment options, hospitals account for a sizeable portion.

Geographically, the market for chronic gingivostomatitis treatments is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America holds the greatest market share due to the region's high prevalence of chronic gingivostomatitis and its superior healthcare infrastructure. Increasing investment in research and development activities propels Europe to close the gap quickly. The Asia-Pacific region is anticipated to experience significant development as a result of rising healthcare expenditures and the improvement of healthcare facilities.

Globally, the chronic gingivostomatitis treatment market is poised for substantial expansion. Increasing prevalence, growing awareness, and the demand for advanced treatment options are significant factors driving market growth. However, difficulties associated with limited treatment options must be addressed. By segmenting the market based on treatment type, end-users, and geography, market participants can better comprehend the market's dynamics and capitalise on its opportunities.

About KD Market Research Insights: KD Market Research Company is a reputable and industry-leading market research firm that offers insightful insights, Analytics, and Research Reports for a variety of industries. With an emphasis on providing accurate and actionable market insights and data, our team of experienced research analysts conducts exhaustive research to assist businesses in making informed decisions. Whether you require market forecasts, competitive analysis, or the identification of trends, we offer comprehensive solutions tailored to your specific requirements. Stay ahead of the competition with the dependable market research services of KD Market Research Company.

[healthcare-domain]

Osteoarthritis Therapeutics Market worth $11.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

According to the new market research report "Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs)-Global Forecast to 2025", published by MarketsandMarkets™, the global market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.

Browse in-depth TOC on "Osteoarthritis Therapeutics Market"

185 – Tables 43 – Figures 201 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994

The growth of this market is driven by significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries.

"Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."

Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.

"Viscosupplementation agents is expected to hold the largest share of the market, in 2020."

Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmented into naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Viscosupplementation effectively eases the pain of osteoarthritis through injections that fill up the joint's synovial fluid, thus offering better lubrication of the joints.

"Parental route is expected to hold the largest share of the market in 2020."

On the basis of route of administration, the market has been segmented into oral, topical, and parenteral routes. The parenteral route accounted for the largest share of this market in 2019 and is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the wide adoption of the parenteral route for administering osteoarthritis therapeutics owing to the ease of administration and the better pharmacokinetics and pharmacodynamics, resulting in better patient compliance.

"Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2020."

Based on the distribution channel, the market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. In 2019, hospital pharmacies accounted for the largest share of this market because of the high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies. Reimbursements can also be claimed easily on hospital pharmacy purchases, which is another important draw.

"Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2020."

Based on the purchasing pattern, the market is segmented into OTC and prescription drugs. In 2019, the prescription drugs segment accounted for a larger share of this market as most osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are only available on prescription.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209565994

"Europe commanded the largest share of the market in 2020."

On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, Europe commanded the largest share of the market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents.

[harshnews]

Infantile Hemangioma Market Size, Share, Trends, Growth Opportunities and Competitive Outlook

"Global Infantile Hemangioma Market - Industry Trends and Forecast to 2028

Global Infantile Hemangioma Market, By Treatment Type (Medication, Surgery, Laser Treatment), Drug Type (Beta-Blocker and Steroids), Route of Administration (Oral, Injectables and Others), Diagnosis (X-Ray, Computerized Tomography (CT) Scans, Biopsy, Angiogram and Others), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Access Full 350 Pages PDF Report @

**Segments**

- By Type: The infantile hemangioma market can be segmented into superficial hemangioma, deep hemangioma, and mixed hemangioma. Superficial hemangiomas are closer to the skin's surface and may appear bright red, while deep hemangiomas are located further in the skin and may have a bluish hue. Mixed hemangiomas exhibit characteristics of both superficial and deep hemangiomas.

- By Treatment: Treatment options for infantile hemangiomas include oral beta-blockers, topical beta-blockers, corticosteroids, laser therapy, and surgery. Oral beta-blockers like propranolol are commonly used for treating larger or problematic hemangiomas, while topical beta-blockers may be prescribed for smaller hemangiomas. Corticosteroids can also be administered orally or via injections to reduce the size of the hemangioma.

- By End-User: The infantile hemangioma market caters to hospitals, clinics, ambulatory surgical centers, and homecare settings. Hospitals are the primary end-users due to the complexity of some hemangioma cases that require specialized care and monitoring. Clinics and ambulatory surgical centers may also provide treatment options for less severe hemangiomas, while homecare settings support ongoing management and monitoring of hemangiomas.

**Market Players**

- GlaxoSmithKline plc: GlaxoSmithKline plc offers pharmaceutical products for treating infantile hemangiomas, including oral and topical medications. The company focuses on research and development to introduce innovative treatments for hemangioma management.

- Pfizer Inc.: Pfizer Inc. is another key player in the infantile hemangioma market, providing a range of pharmaceutical options for hemangioma treatment. The company's products aim to address the specific needs of patients with different types of hemangiomas.

- Novartis AG: Novartis AG is actively involved in the infantile hemangioma market, offering treatment options such as beta-blockersGlaxoSmithKline plc, Pfizer Inc., and Novartis AG are prominent players in the infantile hemangioma market, each contributing unique offerings to cater to the needs of patients with this condition. GlaxoSmithKline plc stands out for its focus on research and development, investing in innovative treatments aimed at managing hemangiomas effectively. With a portfolio that includes oral and topical medications, the company is at the forefront of developing new solutions to improve patient outcomes and enhance quality of life.

Pfizer Inc. is another major player in the infantile hemangioma market, known for its diverse range of pharmaceutical options tailored to address the specific requirements of patients with different types of hemangiomas. The company's commitment to advancing healthcare through groundbreaking research and development initiatives has positioned it as a key player in the market, with a focus on providing effective treatment options that meet the evolving needs of patients and healthcare providers.

Novartis AG is also actively engaged in the infantile hemangioma market, offering treatment options such as beta-blockers that have shown promise in managing the condition. With a strong emphasis on innovation and providing comprehensive healthcare solutions, Novartis AG plays a vital role in driving advancements in hemangioma treatment and care. The company's dedication to improving patient outcomes and enhancing treatment efficacy underscores its significant presence in the market.

As the infantile hemangioma market continues to evolve, these market players are poised to make significant contributions through ongoing research, development, and innovation. By introducing novel treatment options, investing in advanced therapies, and collaborating with healthcare providers and stakeholders, GlaxoSmithKline plc, Pfizer Inc., and Novartis AG are instrumental in shaping the future of hemangioma management. With a focus on improving patient care, enhancing treatment modalities, and addressing unmet medical needs, these companies are key drivers of growth and innovation in the infantile hemangioma market.**Segments**

- **By Type:** The infantile hemangioma market can be segmented into superficial hemangioma, deep hemangioma, and mixed hemangioma. Superficial hemangiomas are closer to the skin's surface and may appear bright red, while deep hemangiomas are located further in the skin and may have a bluish hue. Mixed hemangiomas exhibit characteristics of both superficial and deep hemangiomas.

- **By Treatment:** Treatment options for infantile hemangiomas include oral beta-blockers, topical beta-blockers, corticosteroids, laser therapy, and surgery. Oral beta-blockers like propranolol are commonly used for treating larger or problematic hemangiomas, while topical beta-blockers may be prescribed for smaller hemangiomas. Corticosteroids can also be administered orally or via injections to reduce the size of the hemangioma.

- **By End-User:** The infantile hemangioma market caters to hospitals, clinics, ambulatory surgical centers, and homecare settings. Hospitals are the primary end-users due to the complexity of some hemangioma cases that require specialized care and monitoring. Clinics and ambulatory surgical centers may also provide treatment options for less severe hemangiomas, while homecare settings support ongoing management and monitoring of hemangiomas.

**Global Infantile Hemangioma Market, By Treatment Type (Medication, Surgery, Laser Treatment), Drug Type (Beta-Blocker and Steroids), Route

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Infantile Hemangioma Market

Chapter 3: Regional analysis of the Global Infantile Hemangioma Market industry

Chapter 4: Infantile Hemangioma Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Core Objective of Infantile Hemangioma Market:

Every firm in the Infantile Hemangioma Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Infantile Hemangioma Market and growth rate factors.

Important changes in the future Infantile Hemangioma Market.

Top worldwide competitors of the Market.

Scope and product outlook of Infantile Hemangioma Market.

Developing regions with potential growth in the future.

Tough Challenges and risk faced in Market.

Global Infantile Hemangioma top manufacturers profile and sales statistics.

Regional Analysis for Infantile Hemangioma Market:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

Browse Trending Reports:

Mhealth Solutions Market Telecom Cloud Billing Market Industrial Cooking Fire Protection Systems Market Food Manufacturing Market Natural Surfactant Market Industrial Networking Solutions Market Facility Management Market Cathode Materials Market High Purity Gases Market Cassava Starch Market Embedded Connectivity Solutions Market Central Fill Pharmacy Automation Market Rfid In Healthcare Market Virtual Pipeline Systems Market Fiberoptic Phototherapy Equipment Market Suture Passer Market Baby Apparel Market Peanut Allergy Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[researchindustry]

Sunburn Treatment Market Dynamic Outlook and Influencing Key Growth

sunburn treatment market is growing at a substantial CAGR in the forecast period of 2019-2026. Sunburn is a type of irritation and skin burning resulting from the over exposure to sun or ultraviolet light. Regular exposure to sun or ultraviolet light increases the risk of having wrinkles, dark spots and skin cancer. Sign and symptoms include redness, painful or itchy skin.

Segmentation: Global Sunburn Treatment Market

·         By Mechanism of Action (NSAIDs, Corticosteroid, Moisturizer and Others)

·         By Drugs (Lidocaine, Naproxen, Hydrocortisone, Aloevera and Others)

·         By Treatment (Medication, Topical Therapy and Home Remedies), Route of Administration (Oral, Topical and Others)

·         By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

Get Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sunburn-treatment-market

Key Market Players:

The key market players in the global sunburn treatment market are Novartis AG, Boiron USA, dermalogica, Edgewell Personal Care, WELMEDIX LLC, Johnson & Johnson Services, Inc, Bayer AG, Beiersdorf AG, Unilever, ELCA Cosmetics Pvt Ltd, Solar Recover & Zausner LLC, Clinique Laboratories, llc, Water-Jel Technologies, Patanjali Ayurved, Sun Pharmaceutical Industries Ltd, L’Oréal International among others.

Competitive Analysis: Global Sunburn Treatment Market

Global sunburn treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of sunburn treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

·         Adverse effects of exposure to ultraviolet (UV) radiation caused by global warming has fueled the market growth

·         Impact of depleting stratospheric ozone has been linked to the prevalence of sunburn and melanoma skin cancer which is driving the market growth

·         All age groups people are quite vulnerable to the harmful exposure of UV radiation which acts as a major factor in driving the growth of this market

Market Restraints

·         Availability of several natural alternative products is restraining the market growth

·         Predominant demand for sunscreen and sun protection products also acts as a factor restricting this market growth

·         Lack of knowledge amongst huge population in developing countries regarding sunburn is acting as a restricting factor for the market growth

Want Full Report? Enquire Here@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-sunburn-treatment-market    

Reasons to Purchase this Report:

·         Current and future of global sunburn treatment market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Psoriasis Treatment Market

Retinal dystrophy treatment market   

[fullcycledream]

Applications and Regional Insights during the Forecasted Period 2020-2030: Global Immune Thrombocytopenia Market:

Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and anti-phospholipid syndrome. The prevalence of these diseases is high across the world.

The global immune thrombocytopenia market accounted for US$ 3.04 billion in 2019 and is estimated to be US$ 3.3 billion by 2029 and is anticipated to register a CAGR of 0.30%.

The report "Global Immune Thrombocytopenia Market, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

In In July 2019, Intas Pharmaceuticals, took a revolutionary step towards making therapy for chronic immune thrombocytopenia more accessible. The company launched Romiplostim in India under the name Romy.

In December 2018, Amgen got FDA approval for its Nplate (Romiplostim) drug, which is used for the treatment of pediatric patients one year of age and older with immune thrombocytopenia.

Analyst View:

Increasing Second- And Third-Line Therapies

The market is widely driven by increasing second- and third-line therapies. Moreover, the understanding of the disorder and therapeutic has expanded greatly, owing to the increased demand for therapy in the near future. Second-line drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids and danazol, the immunosuppressants cyclophosphamide, azathioprine, cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab. For instance, in January 2020, Rigel Pharmaceuticals, Inc. announced the launch of TAVLESSE (Spleen tyrosine kinase inhibitor) in Europe with its collaborative partner Grifols S.A. The product was launched in Germany and the United Kingdom.

Rising Awareness

Advanced 3-D printing technologies which makes the manufacturing easy and less time consuming is estimated to fuel the demand of metal forming equipment in the global market in the coming future. Manufacturers are involved in improving the quality of metal forming equipment present in the market, this will enforce the consumer to replace their old metal forming equipment with the novel machines and this will accelerate the demand of metal forming equipment. Moreover, the automobile industry is continuously demanding for new and advanced metal forming equipment in the current rapid industrialization stage in the developed as well as developing economies across the globe.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Immune Thrombocytopenia Market”, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029

Key Market Insights from the report:        

The global immune thrombocytopenia market accounted for US$ 3.04 billion in 2019 and is estimated to be US$ 3.3 billion by 2029 and is anticipated to register a CAGR of 0.30%. The market report has been segmented on the basis of type, treatment and distribution channel.

Depending upon the type, The Chronic Immune thrombocytopenia segment is expected to have lucrative growth and accounted for significant market share during the forecast period. Technical advancement in this field of research plays a crucial role. For instance, it has the potential to help develop effective, safe medications for the chronic ITP, thereby expected to have high demand in the near future.

Based on the treatment, the corticosteroids segment is expected to have the largest market share among the other segments during the forecast period. This is attributed to the widespread application of corticosteroids to effectively influence healthcare outcomes. Moreover, it is the most common form of treatment owing to its potential benefits.

In terms of distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Others. Hospital Pharmacy are estimated to have the largest market share.

By region, North America dominated the market with a revenue of USD 901.2 million in 2019 due to the increased demand for Immune thrombocytopenia. Since corticosteroid are considered to be the first line of therapy for the disease, it is expected to have high application rate contributing to its significant share.

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Immune-Thrombocytopenia-ITP-Market-4578

Competitive Landscape:

The prominent player operating in the global immune thrombocytopenia market includes includes Amgen Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals, Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., Saol Therapeutics.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning

Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.

Detailed analysis of the market revenue over the forecasted period.

Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.

Study on the segments that are anticipated to dominate the market.

Study on the regional analysis that is expected to register the highest growth over the forecast period

Key Topics Covered

Introduction

Study Deliverables

Study Assumptions

Scope of the Study

Research Methodology

Executive Summary

Opportunity Map Analysis

Market at Glance

Market Share (%) and BPS Analysis, by Region

Competitive Landscape

Heat Map Analysis

Market Presence and Specificity Analysis

Investment Analysis

Competitive Analysis

To know more

Contact Us:

Sales

Prophecy Market Insights

Email- sales@prophecymarketinsights.com

[data-bridge-market-research]

Asia-Pacific Topical Corticosteroids Market is Dominated by LEO Pharma, Followed by Glaxosmithkline Plc and Pfizer Inc.

Asia-Pacific Topical Corticosteroids Market is expected to reach USD 837.11 million by 2024, from USD 506.28 million in 2016 growing at a CAGR of 6.5% in the forecast period 2017 to 2024. The factors such as increasing prevalence of chronic disease or condition, rise in aging population, growth in topical drug delivery, increasing research and development, new product launches are furthermore boosting the growth of the global topical corticosteroids market. On the other hand, expiry of patent for drugs, weak reimbursement policies, and stringent regulatory policies may hinder the growth of the market. The topical corticosteroids market in the Asia-Pacific region is leading in Japan. Click Here For Free Sample Report @ databridgemarketresearch.com/request-a-sample/?dbmr=asia-... Market Segmentation: Asia-Pacific Topical Corticosteroids Market The Asia-Pacific topical corticosteroids market is segmented on the basis of molecule name, brands, purchase mode, application, medication type, potency class, end user, distribution channel. On the basis of molecule name, Asia-Pacific topical corticosteroids market is segmented into fludroxycortide, triamcinolone acetonide, fluocinolone acetonide, antiseptics, betamethasone, clobetasone propionate, clobetasone butyrate, halobetasone, mometasone, and others. In 2017, Fludroxycortide is expected to dominate the Asia-Pacific topical corticosteroids market with 26.2% market share and is expected to reach USD 229.42 million by 2024, growing at a CAGR of 7.2% in the forecast period 2017 to 2024. On the basis of purchase mode, Asia-Pacific topical corticosteroids market is segmented into segmented into OTC-based and prescription-based. In 2017, prescription market segment is expected to dominate the Asia-Pacific topical corticosteroids market with 71.6% market share and is expected to reach USD 609.60 million by 2024, growing at the highest CAGR of 6.8% in the forecast period 2017 to 2024. The Asia-Pacific topical corticosteroids market, on the basis of brands is segmented into betnovate, betnovate N, panderm plus, lobate, cosvate G, clop G, tenovate GN, lobate GM, ultiderm, flutivate, fexin, momate, candiderm, and others. On the basis of application, Asia-Pacific topical corticosteroids market is segmented into acne, dermatitis, psoriasis, skin infection, hyperpigmentation, melasma and others. In 2017, psoriasis is expected to dominate the Asia-Pacific topical corticosteroids market with 42.5% market share and is expected to reach USD 370.88 million by 2024, growing at the highest CAGR of 7.1% in the forecast period 2017 to 2024. The Asia-Pacific topical corticosteroids market is segmented based on medication type into ointments, creams, liquid & solutions, lotions, gel, oils, pastes, sprays, and others. In 2017, ointments is expected to dominate the Asia-Pacific topical corticosteroids market with 32.1% market share and is expected to reach USD 261.05 million by 2024, growing at a CAGR of 6.1% in the forecast period 2017 to 2024. However, lotions is expected to grow at the highest CAGR of 7.8% in the forecast period, and is expected to reach USD 93.99 million in 2024 from USD 51.55 million in 2016. The Asia-Pacific topical corticosteroids market is segmented based on potency class into moderate, mild, ultra-high, and high. In 2017, moderate is expected to dominate the Asia-Pacific topical corticosteroids market with 41.4% market share and is expected to reach USD 359.89 million by 2024, growing at the highest CAGR of 7.1% in the forecast period 2017 to 2024. View Full Report @ databridgemarketresearch.com/reports/asia-pacific-topical... The Asia-Pacific topical corticosteroids market is segmented based on end-user into three notable segments; hospital, dermatology clinics, homecare and others. In 2017, dermatology clinics is expected to dominate the Asia-Pacific topical corticosteroids market with 44.4% market share and is expected to reach USD 387.44 million by 2024, growing at the highest CAGR of 7.1% in the forecast period 2017 to 2024. The Asia-Pacific topical corticosteroids market is segmented based on distribution channel into four notable segments; hospital pharmacies, pharmacy stores, online pharmacies and others. In 2017, pharmacy stores is expected to dominate the Asia-Pacific topical corticosteroids market with 44.6% market share and is expected to reach USD 390.11 million by 2024, growing at the highest CAGR of 7.2% in the forecast period 2017 to 2024. Key Drivers: Asia-Pacific Topical Corticosteroids Market Asia-Pacific topical corticosteroids market is growing with the increasing prevalence of chronic disease or condition, rise in aging population, growth in topical drug delivery, increasing research and development, new product launches are furthermore boosting the growth of the global topical corticosteroids market. Key Points: Asia-Pacific Topical Corticosteroids Market Asia-Pacific topical corticosteroids market is dominated by LEO Pharma, followed by Glaxosmithkline Plc and Pfizer Inc. Fludroxycortide segment is expected to dominate the Asia-Pacific topical corticosteroids market. The topical corticosteroids market in the Asia-Pacific region is leading in Japan, China, India and South Korea. Japan accounts for the highest market share in this region. For More Details In-Depth Enquiry @ databridgemarketresearch.com/inquire-before-buying/?dbmr=... Related Report Global Topical Corticosteroids Market – Industry Trends and Forecast to 2024 Global Topical Corticosteroids Market By Molecule Name (Fludroxycortide, Triamcinolone Acetonide, Fluocinolone Acetonide, Antiseptics, Betamethasone, Clobetasone Propionate, Clobetasone Butyrate, Halobetasone, Mometasone, Others), Brands, Purchase Mode (OTC-Based, Prescription-Based), Application, Medication Type, Potency Class, End User (Hospital, Dermatology Clinics, Homecare, Others), Distribution Channel, Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2024 Report Access: databridgemarketresearch.com/reports/global-topical-corti... About Data Bridge Market Research: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Contact: Vishal Dixit Data Bridge Market Research Tel: +1-888-387-2818 Email: Sales@databridgemarketresearch.com Website: databridgemarketresearch.com

[healthcaredbmrnews]

Mouth ulcers treatment market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3.95% in the above mentioned forecast period.